80% (n = 8) of the triple-negative breast cancers had CAIX expression levels above median (p = 0.003), compared to 69.2% among the Her2 + subtype (n = 9) and 18.8% (n = 3) of the HR + Her2- group. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.